Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Carcinoma, Hepatocellular × Doxorubicin × Clear all

Phase

Status

Sponsor Class

OTHER 26 INDUSTRY 8 NIH 7 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Lymphoma, T-Cell, Peripheral 2 Sarcoma 1 Rhabdomyosarcoma 1 Osteosarcoma 1 Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1 Carcinoma, Hepatocellular 1

Interventions

tislelizumab 3 Sorafenib 3 Propranolol 3 ledipasvir 2 donafenib 2 Sofosbuvir 2 Ribavirin 2 Radiotherapy 2 Proton Therapy 2 Bevacizumab 2 sitravatinib 1 palbociclib 1 lenvatinib 1 ledipasvir, sofosbuvir drug combination 1 envafolimab 1 entecavir 1 elbasvir-grazoprevir drug combination 1 daclatasvir 1 atezolizumab 1 Vitamin D 1 Urination 1 Tyrosine Kinase Inhibitors 1 Simeprevir 1 Raltegravir Potassium 1 Radiosurgery 1 Psychotherapy, Multiple 1 Patient Education as Topic 1 Nadolol 1 Doxorubicin 1 Control Groups 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00990860 2011-01-05

START

Taipei Veterans General Hospital, Taiwan

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡